Journal Cover
Nature Reviews Drug Discovery
Journal Prestige (SJR): 10.106
Citation Impact (citeScore): 10
Number of Followers: 385  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1474-1776 - ISSN (Online) 1474-1784
Published by NPG Homepage  [138 journals]
  • CAR-T cells combat cardiac fibrosis
    • Nature Reviews Drug Discovery, Published online: 13 September 2019; doi:10.1038/d41573-019-00162-0

      CAR-T cells combat cardiac fibrosisNature Reviews Drug Discovery, Published online: 2019-09-13; doi:10.1038/d41573-019-00162-02019-09-13
      DOI: 10.1038/d41573-019-00162-0
       
  • Avoiding target misidentification
    • Nature Reviews Drug Discovery, Published online: 12 September 2019; doi:10.1038/d41573-019-00161-1

      Avoiding target misidentificationNature Reviews Drug Discovery, Published online: 2019-09-12; doi:10.1038/d41573-019-00161-12019-09-12
      DOI: 10.1038/d41573-019-00161-1
       
  • A probe for every protein
    • Nature Reviews Drug Discovery, Published online: 11 September 2019; doi:10.1038/d41573-019-00159-9

      Target 2035 — an ambitious open-science proposal to develop a suite of chemical genomics tools to modulate every protein in the proteome — faces many challenges ahead.Nature Reviews Drug Discovery, Published online: 2019-09-11; doi:10.1038/d41573-019-00159-92019-09-11
      DOI: 10.1038/d41573-019-00159-9
       
  • Stanley Crooke
    • Nature Reviews Drug Discovery, Published online: 10 September 2019; doi:10.1038/d41573-019-00157-x

      In 1989, Stanley Crooke left his job heading up R&D at Smith Kline Beckman, a predecessor of the pharmaceutical giant GlaxoSmithKline, to found and run the antisense-oligonucleotide start-up Ionis Pharmaceuticals (initially called Isis Pharmaceuticals). With just over US$5 million funding at the time, Crooke’s ambitious plan was not just to develop a new RNA-targeted modality that could lower protein expression, but also to tackle industry’s productivity crisis while delinking drug development from commercialization. As broader interest in antisense technologies waxed and waned, Ionis faced some tough years. But it now has three antisense products on the market with partners, three products including a pioneering treatment for Huntington disease in phase III trials and more than ten candidates that could enter phase III trials by the end of 2020. After 30 years at the helm of Ionis as CEO, Crooke will transition to the executive chairman role in January. He spoke with Asher Mullard about Ionis’s long road to success, and the future of antisense drug technology.Nature Reviews Drug Discovery, Published online: 2019-09-10; doi:10.1038/d41573-019-00157-x2019-09-10
      DOI: 10.1038/d41573-019-00157-x
       
  • Author Correction: Adaptive platform trials: definition, design, conduct
           and reporting considerations
    • Nature Reviews Drug Discovery, Published online: 10 September 2019; doi:10.1038/s41573-019-0045-0

      Author Correction: Adaptive platform trials: definition, design, conduct and reporting considerationsNature Reviews Drug Discovery, Published online: 2019-09-10; doi:10.1038/s41573-019-0045-02019-09-10
      DOI: 10.1038/s41573-019-0045-0
       
  • Upcoming market catalysts in Q4 2019
    • Nature Reviews Drug Discovery, Published online: 09 September 2019; doi:10.1038/d41573-019-00156-y

      Upcoming market catalysts in Q4 2019Nature Reviews Drug Discovery, Published online: 2019-09-09; doi:10.1038/d41573-019-00156-y2019-09-09
      DOI: 10.1038/d41573-019-00156-y
       
  • Gene therapy boom continues
    • Nature Reviews Drug Discovery, Published online: 06 September 2019; doi:10.1038/d41573-019-00154-0

      Gene therapy boom continuesNature Reviews Drug Discovery, Published online: 2019-09-06; doi:10.1038/d41573-019-00154-02019-09-06
      DOI: 10.1038/d41573-019-00154-0
       
  • FDA notches up third tissue-agnostic cancer approval
    • Nature Reviews Drug Discovery, Published online: 06 September 2019; doi:10.1038/d41573-019-00155-z

      FDA notches up third tissue-agnostic cancer approvalNature Reviews Drug Discovery, Published online: 2019-09-06; doi:10.1038/d41573-019-00155-z2019-09-06
      DOI: 10.1038/d41573-019-00155-z
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 34.226.234.20
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-